



Plenary Sessions: <i>New Zealand Rooms 3 & 4</i>			
10.00-10.15am	Conference Opening His Worship, the Mayor of Auckland City Hon. John Banks QSO <i>Chair: Maxine Simmons, Director, BioCatalyst</i>		
10.15-10.30am	Conference Welcome Bronwyn Dilley, Chief Executive Officer, NZBIO		
10.30-11.15am	"State of the Industry: The Global Perspective" Dr Ben Chen, International Director, Burrill & Co		
11.15 - 12.00pm	"Can New Zealand Build an International Pharmaceutical Company: The Pharmaxis Story" Dr Alan Robertson, Chief Executive Officer, Pharmaxis <i>Plenary Chair: Scott Kerse, Partner, PricewaterhouseCoopers</i>		
12.00-1.00pm	Lunch - <i>Exhibition Hall</i>		
	Stream 1	Stream 2	
	<i>New Zealand Room 3</i>	<i>New Zealand Room 4</i>	
	Healthy, Wealthy & Wise:		
	The Social & Economic Potential of a Vibrant Human Therapeutics Industry in NZ	East Meets West: Untapped Opportunities in the Asia Pacific Region	
	Investor & Technology Showcase	Marlborough Rooms 2&3	
	Meet the Investors		
1.00-2.30pm	<p>"Policy Options to Support the Drug Development Industry in New Zealand" Michelle Lockhart, PhD Student, University of Auckland</p> <p>"Holding Our Own and Being Expansive in the Global Pharmaceutical Market - An Industry Perspective" Peter Surman, Manager, Research & Development, Douglas Pharmaceuticals</p> <p>"Title tba" Dr Joshua Funder, Partner, GBS Ventures</p> <p>"Botanical Drugs: The Way of the Future?" Larry Stenswick, Director, Migco Pharmaceuticals</p> <p><i>Chair: Dr Phil Kearney, Manager, External Scientific Affairs, Merck Sharpe & Dohme</i></p>	<p>Sponsored by BioNet Asia Pacific</p> <p>"Riding the Tail of the Dragon" Dr Allen Goldenthal, Director, Valley Animal Research Centre</p> <p>"A Canadian Vision for the BioEconomy" Philip Schwab, VP Industry Relations, BIOTECANADA</p> <p>"Leveraging the Asia Pacific Opportunity - A Victorian Perspective" Dr Amanda Caples, Director Biotechnology & Science & Technology Programmes, Department Innovation Industry & Regional Development, State of Victoria</p> <p><i>Chair: Peter Landon-Lane, Chief Executive Officer, Plant & Food Research</i></p> 	<p>Nick Peace, Investment Director, Starfish Ventures</p> <p>Duncan Mackintosh, Manager, AngelLink</p> <p>Brent Ogilvie, Director, Pacific Channel</p> <p>Paul D'Sylva, Ample Luck Securities</p> <p><i>Chair: Maxine Simmons, Director, BioCatalyst</i></p>
2.30-4.00pm	<p>The Importance of Regulation & Stakeholder Dialogue</p> <p>"Referees, Regulators, & other Ratbags" Rob Forlong, Chief Executive Officer, ERMA</p> <p>"The Commercial Impacts of Regulation: Costs, Competition & Commercialisation" Gus Hazel, Senior Associate, Baldwins</p> <p>"It Can be Done! The Approval of the GM Equine Influenza Vaccine in New Zealand, Case Study" Glenda Hughes</p> <p>"Regulation of Genetically Engineered Organisms by USDA - New Technologies, New Challenges" Terri Dunahay, Ian Axford Fellow, MORST/USDA</p> <p><i>Chair: Dr William Rolleston, Production Director, South Pacific Sera</i></p>	<p>Working with CROs for Effective Early Product Development in Australasia</p> <p>"High-Quality, Cost-Effective Preclinical Product Development Solutions" Rose-Marie Pennisi, Commercial Manager, TetraQ</p> <p>"Different Models for Research Collaborations between Sponsors & CROs" Dr Jane Eagleson, Business Development Manager, Argenta</p> <p>"Early Phase Clinical Trials: Opportunities for Australasian Biotech Companies from The Regulatory Perspective!" Dr Dianne Jackson-Matthews, Deputy Group Director of Regulatory Affairs, ERA Consulting</p> <p>"Bringing Early Phase Product Development Strategies in Practice" Gerard Dunne, Managing Director, BELTAS</p> <p><i>Chair: Shaun Coffey, Chief Executive Officer, Industrial Research Limited</i></p>	<p>"Innate Therapeutics Immune Modulating Microparticle - a Second Generation Approach to Immune Modulation" Peter Bradley, Chief Business Development Officer, Innate Therapeutics</p> <p>"Science Provider, Regulator, Stake Holder - Win, Win, Win for Aquaculture" Paul McNabb, Technical Manager, Cawthron Institute</p> <p>"Personalised Modelling for Risk of Disease & Clinical Outcome Prognosis" Prof Nikola Kasabov, Director & Founder of KEDRI, Auckland University of Technology</p> <p>"Future human central nervous system therapies will be dominated by highly potent and efficacious drugs" Frank Sieg, Chief Scientific Officer, CuronZ</p> <p><i>Chair: Candace Toner, Chief Executive Officer, Biomatters</i></p>
4.00-4.30pm	Afternoon Tea - <i>Exhibition Hall</i>		
4.30-6.00pm	<p>Eat Yourself Healthy: Functional Foods for Health</p> <p>"Food Innovation" Dr Kieran Elborough, General Manager of Science for Food Innovation, Plant & Food Research</p> <p>"The Health Benefits of ZESPRI GOLD Kiwifruit: Building the Body's Shield" Dr Margot Skinner, Principal Scientist, Food Innovation, Plant & Food Research</p> <p>"Coming to the Table: Stakeholder Dialogue & Strategic Investments in Food Innovation" Dr Karen Cronin, Science Leader, ESR & Prof Gerald Midgley, Senior Science Leader, ESR</p> <p>"In the Mix: International Developments on the Regulation of Food & Therapeutic Products" Kate McHaffie, Senior Associate, AJ Park</p> <p><i>Chair: Mike Morgan, Partner, PricewaterhouseCoopers</i></p>	<p>Advancing New Zealand's Bioeconomy: Commercialisation Success Stories</p> <p>"Process Development & Commercialisation at NZP" Dr Selwyn Yorke, Market Development Manager, New Zealand Pharmaceuticals</p> <p>"Turning Ideas Into Market-led Revenue Generating Products" Dr Peter Foster, Chief Executive Officer, Symansis</p> <p>"Developing a World Class Extraction Industry in New Zealand" Dr Owen Catchpole, Group Leader Integrated Bioactive Technologies, Industrial Research Limited & Dr Andy Herbert, Chief Scientific Officer, NutriZeal & Chairman of Nutriventures/IRL Development Alliance</p> <p>"Manufacturing a World-First Cell Therapeutic in New Zealand" Dr Paul Tan, Chief Executive Officer, Living Cell Technologies</p> <p><i>Chairs: Dr Owen Catchpole, Group Manager, Integrated Bioactive Technologies, Industrial Research Limited & Dr Andy Herbert, Chief Scientific Officer, NutriZeal & Chairman of Nutriventures/IRL Development Alliance</i></p>	<p>Novel Therapies, Lead Identification & Drug Delivery</p> <p>"Discovery to Drug, The Commercialisation Challenges" Judy Halliday, Commercialisation Manager, Life Sciences, UniQuest</p> <p>"Molecules, Mice, to Men: Translation of Targeted Therapeutics for Advanced Prostate Cancer" Prof Colleen Nelson, Director & Chair of the Australian Prostate Cancer Research Centre, Institute of Health & Biomedical Innovation</p> <p>"Cell Therapy Product Development: A Regulatory Perspective" Dr Dianne Jackson-Matthews, Deputy Group Director of Regulatory Affairs, ERA Consulting</p> <p>"Nanotechnology-Based Anticancer Drug Delivery Systems" Associate Professor Sanjay Garg, Deputy Head of School, School of Pharmacy, University of Auckland</p> <p><i>Chair: Prof Peter Shepherd, Professor of Cellular Signalling, University of Auckland</i></p>
6.00-7.30pm	 <p>WaikatoLink International Networking Reception <i>"Connecting New Zealand to the World"</i> Exhibition Hall, Level 5, SKYCITY Convention Centre</p>		

This programme is subject to change



NZBIO 2010: Advancing a Bio-Based Economy
22-24 March 2010
Day 2: Tuesday 23 March 2010


Plenary Sessions: <i>New Zealand Rooms 3 & 4</i>			
9.00-9.40am	<p>"Commercialisation of GM Crops: Putting Science into Farmers' Hands" Joshua Hofheimer, Chief Executive Officer, Hexima Limited</p>		
9.40-10.20am	<p>"From Waste to Fuels & Chemicals" Sir Stephen Tindall KNZM, K1W1</p> <p><i>Plenary Chair: Mike Sage, Partner, Simpson Grierson</i></p>		
10.20-10.45am	Morning Break - <i>Exhibition Hall</i>		
	Stream 1 <i>New Zealand Room 3</i>	Stream 2 <i>New Zealand Room 4</i>	Investor & Technology Showcase <i>Marlborough Rooms 2&3</i>
10.45-12.00pm	<p>"Sweet As!": New Zealand Food Biotechnologies "Logicane: An Innovative Low GI Functional Food Alternative to Processed Sugar" Dr Jason Smythe, Senior VP & Global Head Research & Development, Horizon Science</p> <p>"Successful Commercialisation of Natural Products through Clinical Trials" Dr Iona Weir, Chief Scientific Officer, Vital Foods</p> <p>"How Venture Capital can Add Value in the Low Margin FMCG Market" Dr Andrew Kelly, Executive Director, BioPacific Ventures</p> <p><i>Chair: Charles Williams, Chief Executive Officer, Seperex</i></p>	<p>Powering New Zealand: Solving the Energy Crisis at Home & Abroad "Renewable Fuels: A Major NZ Bio-Business Growth Opportunity" Dr Ian Maxwell, Chief Executive Officer, Maxall Energy</p> <p>"The Energy-Water Nexus - Aquaflow's Contribution" Nick Gerritsen, Director & Co-Founder, Aquaflow Bionomic Corporation</p> <p>"Creating Something from Nothing - Adding Value to Steel Mill Gases" Dr Sean Simpson, Chief Scientific Officer, Lanzatech</p> <p><i>Chair: Mark Hargreaves, Partner, AJ Park</i></p>	<p>Meet the Investors</p> <p>Dr Phil Kearney, Manager External Scientific Affairs, Merck, Sharp & Dohme</p> <p>Dr Ashley Bates, Head Research & Development Alliances, GlaxoSmithKline</p> <p>Dr Joshua Funder, Partner, GBS Ventures</p> <p>Dean Tilyard, Chief Executive Officer, The Bio Commerce Centre</p> <p><i>Chair: Glenn Cross, Chief Operating Officer, AusBiotech</i></p>
12.00-1.30pm	<p>Communications: PR, IR & Being Heard at Home & Abroad "Capturing Media & Public Attention - IRL's Million Dollar R&D Competition" Mike Eng, Team Leader - Communication, Industrial Research Limited</p> <p>"Why Does Nobody Love Us? Dealing With the Media When You're Not a Big Company" Nick Evans, Editor, BioTechnologyNews.net</p> <p>"Title tba" David Blake, Editor, BioShares</p> <p><i>Chair: Lisa-Marie Richan, Director, Strategic Relations, New Zealand Trade & Enterprise</i></p>	<p>Capital Markets: A Critical Factor in an Effective Innovation Ecosystem PANEL SESSION Dr Shane Storey, Senior Research Analyst (Life Sciences), Wilson HTM</p> <p>Dr Andrew Kelly, Executive Director, BioPacific Ventures</p> <p>"Title tba" Franceska Banga, Chief Executive Officer, New Zealand Venture Investment Fund</p> <p>"Title tba" Dr Joshua Funder, Partner, GBS Ventures</p> <p><i>Chair: Maxine Simmons, Director, BioCatalyst</i></p>	<p>"Metabolics at AgResearch for New Zealand" Scott Harrison, Research Scientist, AgResearch</p> <p>"Greenhouse Gas" Mark Aspin, Consortium Manager, Pastoral Greenhouse Gas Research</p> <p>"A Biotech Approach to Food" Lisa Marcroft, Business Development Manager, AgResearch</p> <p>"Is there a Role for Epigenetics in Agriculture?" Dr Jimmy Suttie, General Manager Science & Technology, AgResearch</p> <p>"ParaCo Technologies Limited" Dr Ian Boddy, General Manager, Commercial, AgResearch</p> <p><i>Chair: Dr Peter Fennessy, Managing Director, AbacusBio</i></p>
1.30-2.30pm	Lunch - <i>Exhibition Hall</i>		
2.30-4.00pm	<p>Is the VC Model Failing? Sponsored by AngelLink PANEL SESSION</p> <p>Andrew Turnbull, ICE Angels</p> <p>Duncan Mackintosh, Manager, AngelLink</p> <p>David Darling, Chief Executive Officer, Pacific Edge Biotechnology</p> <p>Paul D'Sylva, Ample Luck Securities</p> <p><i>Chair: Chris De Boer, Chairman, AngelLink</i></p> 	<p>Capturing Economic Value from Innovative Plant Technologies "Advancing New Zealand's Forests as a Biomass Resource for Future Biorefineries" Dr Elspeth MacRae, Group Manager Biomaterials Research, Scion</p> <p>"Biotech Approaches to Increase Forage Pasture Quality for Ruminant Livestock", Dr Gregory Bryan, Team Leader, AgResearch</p> <p>"Delivering Biotech Forages for Better Pastoral Productivity in New Zealand" Dr Zac Hanley, Manager/Science Leader, Pastoral Genomics</p> <p><i>Chair: Dr Jimmy Suttie, General Manager Science & Technology, AgResearch</i></p>	<p>"Biosensor Development for Detecting Lactose in Dairy Wastewater" Dr. Neil Pasco, Bioelectrochemistry Group Leader, Lincoln Ventures</p> <p>"Fermentation Scale Up & Product Development at IRL" Jason Ryan, Senior Scientist, Industrial Research Limited</p> <p>"A Virus-Based Vaccine Delivery Platform for use in Production Animals" Prof Andrew Mercer, Director, Virus Research Group, University of Otago</p> <p>"Domestic Livestock & Biotechnology: Biomarkers for Heritable Resistance to Infection" Prof Frank Griffin, Director Disease Research Laboratory, University of Otago</p> <p>"SciTOX" Ralph Wattinger, Chief Executive Officer & Co-Founder, SciTOX</p> <p><i>Chair: Dr Max Kennedy, Director Sector Investments - Food & Bio-Products, Industry & Environment, Foundation for Research, Science & Technology</i></p>
4.00-5.30pm	<p>The Never-ending Story: Harnessing the Research, IP, Business Continuum</p> <p>"IP Strategies for Bio Start-Up's" Jason Rogers, Partner, James & Wells</p> <p>"Moving from Research to IP to Business" Gus Hazel, Senior Associate, Baldwins</p> <p>"Creating a World-Wide Intellectual Property Strategy" Dr Benjamin Borson, Founder & President, Borson Law Group (US)</p> <p><i>Chair: Shelley Rowland, Senior Associate, Baldwins</i></p>	<p>The Customer is Always Right: Working with Consumers for Successful Product Development</p> <p>"Managing Innovation within a Global Company: The Impact of Consumers on Innovation Strategy" Dr Jeremy Hill, Chief Technology Officer, Fonterra</p> <p>"Pharmaxis & the Cystic Fibrosis Market" Dr Alan Robertson, Chief Executive Officer, Pharmaxis</p> <p>"Insulin Delivery on Demand" Dr Paul LJ Tan, Chief Executive Officer, Living Cell Technologies</p> <p><i>Chair: Mike Sage, Partner, Simpson Grierson</i></p>	<p>"Novel Genetic Variants that Impact on Thiopurine Drug Responses" Prof. Martin A Kennedy, Research Professor, University of Otago</p> <p>"Enzymes R Us: Enzyme Technology at IRL" Ulrike Hubl, Research Scientist, Industrial Research Limited</p> <p>"New Combination Therapy for Fungal Infections" Dr Alex Tickle, Commercialisation Manager, Otago Innovation</p> <p>"Dynamically Tunable Nanopores for Nanoparticle Detection, Quantitation & Characterisation" Rebecca Warr, Research & Customer Support Manager, Izon Science Ltd</p> <p>"Omega-3 After the Fish are Gone? Addressing the Supply Risk for Pharmaceutical EPA" Greg Moss-Smith, Chief Executive Officer, Photonz Corporation</p> <p><i>Chair: Dr Richard Furneaux, General Manager, Industrial Biotechnologies Cluster, Industrial Research Limited</i></p>
5.30-6.30pm	<p>Student Poster Competition Presentations New Zealand Promenade, Level 5, SKYCITY Convention Centre</p>		
6.30-7.00pm	<p>Pre Dinner Drinks Auckland Promenade, Level 4, SKYCITY Convention Centre</p>		
7.00-10.00pm	<p>NZBIO Annual Excellence Awards Dinner Auckland Rooms 3 & 4, Level 4, SKYCITY Convention Centre</p> 		



This programme is subject to change



NZBIO 2010: Advancing a Bio-Based Economy
22-24 March 2010
Day 3: Wednesday 24 March 2010

Plenary Sessions: <i>New Zealand Rooms 3 & 4</i>			
8.30-9.15am	<p align="center">"How to Successfully Access & Leverage NIH Resources" Claire Driscoll, Director Technology Transfer Office, National Human Genome Research Institute, NIH</p>		
9.15-10.00am	<p align="center">"Bioscientists: Issues & Opinions from the 2008 Survey of Scientists" Dr Jack Sommer, Knight Distinguished Professor of Public Policy Emeritus, University of North Carolina</p> <p align="center"><i>Plenary Chair: Anton Gibson, Partner, AJ Park</i></p>		
10.00-10.15am	Morning Tea - <i>Exhibition Hall</i>		
	Stream 1 <i>New Zealand Room 3</i>	Stream 2 <i>New Zealand Room 4</i>	
	Investor & Technology Showcase <i>Marlborough Rooms 2&3</i>		
10.15-11.30am	<p>Bridging the Ditch: Examples of Successful Trans-Tasman Bio-Based Businesses & Deals</p> <p>"CSL & KODE Biotech = 6 Offspring (and still pregnant)" Prof Steve Henry, Chief Executive Officer, KODE Biotech</p> <p>"Title tba" Craig Reilly, Investment Manager, Trans-Tasman Commercialisation Fund</p> <p>"Growing the Regional Drug Development Industry" Dr Richard Furneaux, General Manager, Industrial Biotechnologies Cluster, Industrial Research Limited</p> <p><i>Chair: Andrew O'Brien, Senior Investment Manager, Trans-Tasman Commercialisation Fund</i></p>	<p>Working with Animals: Animal Testing, BioControl & Ethics - What are our Options?</p> <p>"Reducing Animal Testing: A Tissue Banking Model for NZ" John Grew, Head Business Advisory Services, Innovation Dynamics</p> <p>"Acceptability of Innovative Biotechnologies in the Management of Pest Populations of Possums" Dr Mark Fisher, Director, Kotare Bioethics</p> <p>"Using Animals in Rare Disease Research, Including Transgenic Animals to Produce Therapeutics for Rare Diseases. Time to Do More, Not Less" John Forman, Executive Director, New Zealand Organisation for Rare Disorders</p> <p>"Outsourcing of Preclinical Studies - A Trend Reflecting Regulatory & Business Demands" Dr Christopher Stewart, Senior Director, Asia-Pacific Business Affairs, MPI Research</p> <p><i>Chair: Dr Christopher Stewart, Senior Director, Asia-Pacific Business Affairs, MPI Research</i></p>	<p>"Anti-inflammatory Nutraceuticals Derived from Meat Industry Co-Products" Keryn Johnson, Senior Research Scientist, Industrial Research Limited</p> <p>"Perseis Therapeutics Presentation" Dr Parmjot Bains, Chief Executive Officer, Perseis Therapeutics</p> <p>"Colostrum, R&D from Nature" Peter Lehrke, General Manager, Research & Development, New Image Group</p> <p>"The Sequencing of Genomes of Importance to New Zealand's Bio-Economy" Dr Roger P Hellens, Science Group Leader, Genomics, Plant & Food Research</p> <p>"Real Time Any Time Pregnancy Diagnosis - In Cows" Ed Catherwood, Chief Executive Officer, HEARD Systems</p> <p><i>Chair: Dr Kannan Subramaniam, Chief Executive Officer, Kangela</i></p>
11.30-12.45pm	<p>Money Money Money! Raising Capital in the Post-GFC Market PANEL SESSION</p> <p>Howard Moore, Executive Director, BioPacific Ventures</p> <p>Nick Peace, Investment Director, Starfish Ventures</p> <p>Dr Paul D'Sylva, Venture Partner, Ampleluck International Capital Group</p> <p>David Clarke, Director, Cranleigh Merchant Bankers</p> <p><i>Chair: Dr Ben Chen, International Director, Burrill & Co</i></p>	<p>UN Treaties: Impacts on the Industry</p> <p>"The UN Convention on Biological Diversity & How it Will Impact Biotechnology Research in NZ" -Speaker to be confirmed</p> <p>"Devising a Domestic Regime for Access & Benefits Sharing in New Zealand" Alice Hume, Senior Policy Analyst, Fuels & Crown Resources, Ministry of Economic Development</p> <p>"Climate Change after Copenhagen: What Does it Mean for NZ Bio-Businesses?" John Carnegie, Manager, Energy, Environment & Infrastructure, Business NZ</p> <p><i>Chair: Dr Anna Lavelle, Chief Executive Officer, AusBiotech</i></p>	<p>Session Sponsored by UKTI</p> 
12.45-1.15pm	Lunch - <i>Exhibition Hall</i>		
1.15-2.30pm	<p>It All Comes Back to the People PANEL SESSION</p> <p>Graeme Fielder, Chief Executive Officer, Spark</p> <p>Prof Joerg Kistler, Director, School of Biological Sciences, University of Auckland</p> <p>Candace Toner, Chief Executive Officer, Biomatters</p> <p>Dr Dieter Adam, Operations Director, Food & Beverage & Biotechnology, New Zealand Trade & Enterprise</p> <p>Roger Jordan, Human Resources Leader NZ BioProduction, Life Technologies</p> <p><i>Chair: Roger Branch, Associate Director, Kinross Recruitment</i></p>	<p>Sequencing: Next Generation Business Models</p> <p>"Turning Base-Pairs into Business: Bioinformatics Software for Turning Raw Data into Information" Dr Peter Meintjes, Market Development Manager, Biomatters</p> <p>"DNA Sequencing Technology, Revolutionising Genomics" Dave Edwards, Associate Professor, University of Queensland</p> <p>"Illumina Genome Sequencing: Impact for Human Health & Agriculture" Richard Hodgson, Region Specialist Agrigenomics, Illumina</p> <p><i>Chair: Jeremy Barker, Chief Executive Officer, Queensland Facility for Advanced Bioinformatics</i></p>	<p>NZAQ Bio-Fuels Forum</p>
2.30-2.40pm	Tea/Coffee Break		
2.40-3.30pm	<p align="center">Closing Panel Discussion: "The Prophets: Predictions of What the World will Look Like in 2050" Tony Smale, Maxine Simmons, Ben Chen, Alan Robertson, William Rolleston <i>Chair: Peter Lennox, Group General Manager, Operations, New Zealand Trade & Enterprise</i></p>		
3.30-3.45pm	<p align="center">Conference Close NZBIO Chief Executive Bronwyn Dilley & NZBIO Chair Maxine Simmons</p>		
4.00 - 6.00pm	<p align="center">When LEO Bought Peplin - Fair Deal or Steal?</p> <p>Valuation Workshop with Shane Storey, Senior Research Analyst (Life Sciences) Wilson HTM</p>		

